Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Seer, Inc.NASDAQ: SEER

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$17.26M, compared with -$20.73M a year earlier. Trailing-twelve-month operating income was -$74.65M.

Context

  • Operating income amounted to 486.7% of revenue in FY2025, down 231.0 pp from a year earlier.
  • Operating income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 1 analysts of -$59.4M (+24.3%) for the fiscal year ending Dec 2026, a step up from the +21.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$17.26M+1.5% QoQ
Last fiscal yearDec 2025
-$78.45M+21.6% YoY
LTMMar 2026
-$74.65M+22.0% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.8%+26.9%+10.2 pp
1 year+21.6%+24.3%+2.7 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(78.45M) USD
Year-over-year change
+21.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +22.0% is the 6th highest of 19, against a peer median of +2.2%.
  • Operating income amounts to 496.4% of revenue for SEER, versus a peer median of 345.2%.
SEER Competitors
Operating Income for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$289.66M USD+208.4%—41.3%
MNOVMediciNova, Inc.LTM Mar 2026-$12.92M USD-1.4%—2164.8%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026-$37.12M USD+25.8%——
STTKShattuck Labs, Inc.LTM Mar 2026-$52.66M USD+29.7%—5266.4%
MOLNMolecular Partners AGLTM Mar 2026-CHF 61.98M CHF+2.1%——
SEERSeer, Inc.LTM Mar 2026-$74.65M USD+22.0%—496.4%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-$80.77M USD+17.1%—286.2%
PEPGPepGen Inc.LTM Mar 2026-$81.23M USD+25.7%——
QSIQuantum-Si incorporatedLTM Mar 2026-$96.3M USD+12.7%—5199.8%
CCCCC4 Therapeutics, Inc.LTM Mar 2026-$113.84M USD+2.3%—326.6%
NKTXNkarta, Inc.LTM Mar 2026-$116.31M USD+11.9%——
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026-$148.28M USD-6864.7%—345.2%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026-$149.91M USD-2.2%——
LYELLyell Immunopharma, Inc.LTM Mar 2026-$191.86M USD+46.8%—618909.7%
PHVSPharvaris N.V.LTM Sep 2026-€193.47M EUR-125.1%——
SANASana Biotechnology, Inc.LTM Mar 2026-$237.56M USD-11.7%——
CGEMCullinan Therapeutics, Inc.LTM Mar 2026-$240.35M USD-15.0%——
KYMRKymera Therapeutics, Inc.LTM Jun 2026-$350.18M USD-12.3%—333.5%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026-$370.79M USD-82.6%——
Peer median (excluding SEER) —+2.2%—345.2%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.39M14.69M15.18M13.95M16.12M
Cost of Revenue6.77M14.3M13.73M7.12M14.22M
Gross Profit(374K)384K1.45M6.83M1.9M
Gross Margin-5.8%2.6%9.5%49.0%11.8%
Research & Development29.12M45.8M47.44M50.59M37.77M
Selling, General & Admin42.2M52.63M58.95M56.57M42.58M
Operating Expenses71.32M98.43M106.39M106.93M80.35M
Depreciation & Amortization3.56M5.9M5.58M6.18M6.1M
EBITDA(67.61M)(87.07M)(80.7M)(80.33M)(67.3M)
EBITDA Margin-1057.3%-592.9%-531.5%-575.9%-417.5%
Operating Income(71.7M)(98.04M)(104.94M)(100.1M)(78.45M)
Operating Margin-1121.3%-667.6%-691.2%-717.7%-486.7%
Interest Income326K4.6M17.76M16.67M11.52M
Interest Expense22K0000
Other Income / Expenses527K5.08M18.67M13.6M5.05M
Income Before Tax(71.17M)(92.97M)(86.28M)(86.5M)(73.4M)
Pre-Tax Margin-1113.1%-633.1%-568.3%-620.2%-455.4%
Income Tax Expense00098K201K
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Net Margin-1113.1%-633.1%-568.3%-620.9%-456.6%
EPS (Basic)(1.13)(1.42)(1.35)(1.39)(1.28)
EPS (Diluted)(1.13)(1.42)(1.35)(1.39)(1.28)
Weighted Avg Shares60.86M62.43M63.85M62.35M57.45M
Weighted Avg Shares (Diluted)60.86M62.43M63.85M62.35M57.45M

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.